Clinical trials: Congenital Blindness
Usher Syndrome, Retinitis Pigmentosa
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
- Trial name
- NCT01505062
- Testing
- SAR421869
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Leber Congenital Amaurosis
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
MGT005 is a natural history study to collect longitudinal prospective data from patients with Leber Congenital Amaurosis associated with defects in RPE65.
- Trial name
- NCT02714816
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- MeiraGTx UK II Ltd
Usher Syndrome
Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe
This study aims to characterize Usher patients in order to correlate this data with genetic information. Tasks: Standardization and improvement of Usher syndrome diagnosis: refine and elaborate special tests of visual and…
- Trial name
- EURUSH (NCT01954953)
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Frailty, Vision and Hearing Loss
Health Determinants in Older Adults Living At Home
The observational study will conduct interprofessional assessments by registered nurses, physiotherapists, and occupational therapists of health determinants (i.e., frailty, physical, cognitive, and sensory function, mental and…
- Conditions
- Frailty, Vision and Hearing Loss, Cognitive Function, Social 1, Mental Health Issue
- Trial name
- NCT05837728
- Testing
- Health promoting assessment of older adults living at home
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- University of Stavanger
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Age Related Macular Degeneration, Retinitis Pigmentosa
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive to in healthy and color-blind…
- Conditions
- Age Related Macular Degeneration, Retinitis Pigmentosa, Congenital Stationary Night Blindness, Colorblindness
- Trial name
- NCT02909985
- Testing
- Tungsten halogen light with narrow bandpass filters
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant…
- Trial name
- NCT03597399
- Testing
- AAV2-hRPE65v2,voretigene neparvovec-rzyl
- Where
- 10 sites in United States
- Volunteers
- 87 people
- Sponsor
- Spark Therapeutics, Inc.
Retinitis Pigmentosa (RP), Usher Syndrome
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- NCT07290530
- Testing
- N-acetylcysteine amide
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Retinal Degeneration, Retinitis Pigmentosa
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Patients who are legally blind, caused by retinal degeneration of photoreceptor rods \& cones (e.g. Retinitis pigmentosa), receive a subretinal implant to restore vision partially.
- Trial name
- NCT01497379
- Testing
- surgical implantation of subretinal device
- Where
- Hong Kong
- Volunteers
- 2 people
- Sponsor
- Retina Implant AG
Blindness, Acquired, Blindness Congenital
Effects of Transcranial Direct Current Stimulation With Proprioceptive Training in Blind People
Postural control requires the integration of the vestibular, visual, and somatosensory systems. Vision, in particular, exerts a considerable influence on body sway during activities that require balance.
- Trial name
- NCT03173105
- Testing
- active tDCS, Dynamic proprioceptive exercises, static proprioceptive exercises
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Salgado Institute of Integral Health
Leber Congenital Amaurosis, Retinitis Pigmentosa
Treatment of RP and LCA by Primary RPE Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
- Trial name
- NCT03566147
- Testing
- Human primary Retinal Pigment Epithelial (HuRPE) cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eyecure Therapeutics Inc.
Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl).
- Trial name
- NCT00999609
- Testing
- AAV2-hRPE65v2,voretigene neparvovec-rzyl
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Spark Therapeutics, Inc.
Leber Congenital Amaurosis
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
The purpose of the study is to assess the safety and efficacy of the active substance rAAV-2/4.hRPE65 in patients with Leber Congenital Amaurosis or Congenital severe early-onset retinal degeneration associated with RPE65…
- Trial name
- RPE65 (NCT01496040)
- Testing
- rAAV2/4.hRPE65
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Nantes University Hospital
Amaurosis, Retinal Diseases
Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy
Retinal dystrophies are responsible for numerous cases of blindness, and there are no therapeutic possibilities today. Gene therapy is efficient in a dog model concerning dystrophy linked to a mutation of the rpe65 gene.
- Trial name
- NCT00422721
- Testing
- realization of a family tree, refractometry, evaluation of the presence of a nystagmus
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Nantes University Hospital
Inherited Retinal Dystrophy Due to RPE65 Mutations
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject.
- Trial name
- NCT03602820
- Testing
- AAV2-hRPE65v2
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Hearing and Vision Loss
Validating a Self-fitting Hearing Aid
Eargo, Inc. has developed a hearing aid that contains self-fitting gain software that allows adults with mild-to-moderate hearing loss to test their hearing sensitivity and program hearing aids to match their measured hearing…
- Trial name
- NCT05246904
- Testing
- Fitting algorithm
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Minnesota
Usher's Syndrome
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
- Trial name
- NCT02065011
- Testing
- Blood draw for the laboratory assessment
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Retinitis Pigmentosa, Cone Rod Dystrophy
Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V2). Blind patient suffering from Retinitis Pigmentosa, Cone Rod Dystrophy, or Choroideremia are implanted with an Intelligent…
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Trial name
- IRIS 2 (NCT02670980)
- Testing
- Intelligent Retinal Implant System
- Where
- 9 sites in Austria, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Science Corporation
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor…
- Conditions
- Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
- Trial name
- CLARICO (NCT06789445)
- Testing
- OpCT-001
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- BlueRock Therapeutics
Vision and Hearing Loss, Vision Impairment
SENSE-Brain Health Pro for Older Adults With Sensory Loss
The goal of this study is to learn about the outcomes, usability, and accessibility of the online Brain Health Pro program for older adults with hearing difficulties, vision difficulties, or both.
- Conditions
- Vision and Hearing Loss, Vision Impairment, Hearing Impairment, Vision Difficulty
- Trial name
- SENSE-BHPro (NCT07856888)
- Testing
- Brain Health Pro
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Université de Montréal